Bitwise has become a strategic yield partner in Lombard’s Bitcoin Smart Accounts ecosystem. Bitwise Asset Management has become the first strategic yield partner in Lombard’s Bitcoin Smart Accounts ...

The S100X features a Japanese lacquer finish that takes a month to apply by hand. The S100X features a Japanese lacquer finish that takes a month to apply by hand. is a senior reporter who’s been ...

XRP hit $2.40 in January on a rush of ETF euphoria. Two months later it's back at $1.38, down roughly 43%, and the mood has shifted. Standard Chartered just slashed its year-end XRP price prediction ...

Bitwise’s acquisition of Chorus One expands the company’s staking capabilities to more than 30 blockchains, including Solana, Hyperliquid, Monad, Avalanche and Sui. Crypto asset manager Bitwise has ...

The MarketWatch News Department was not involved in the creation of this content. Appointment adds strategic marketing leadership to sharpen go--to--market execution and drive global growth. CHICAGO, ...

Bitwise contends that the crypto industry's obsession with timing a market bottom overlooks a historical pattern where peak investor anxiety often signals the start of a recovery. Having navigated the ...

The reported acquisition comes as Ethereum staking demand surges, with more than 30% of ETH supply locked and validator wait times stretching beyond 70 days. Bitwise Asset Management is reportedly ...

Over the past 12 months, the Bitwise Crypto Industry Innovators ETF has outperformed Bitcoin. Rather than holding just a single cryptocurrency, the Bitwise ETF holds a diversified portfolio of 29 ...

Artemis seems to be NASA's primary focus. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Breaking space news, the latest updates on rocket ...

The digital asset market is facing a critical fork in the road, according to crypto asset management firm Bitwise. In a Monday blog post, the investment manager warned that the stalling of the Clarity ...

Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may outperform existing treatments from Apellis Pharmaceuticals and Astellas ...